|
Objective: To observe the children with chronic hepatitis B with lamivudine impact on the growth, development and observe its security; analysis of liver function, hepatitis B virologic markers data observed treatment effect for chronic hepatitis B in China children lamivudine to provide a reference. Methods: All patients from August 2006 to August 2009, patients in our clinic and hospitalization. 1, 33 children were randomly selected willing to antiviral therapy for the treatment group, 14 years old, the youngest 2 years old, given lamivudine 3mg / (kg.d), the largest not more than 100mg / d, is necessary to increase licorice diammonium routine therapy. Regular follow-up, were collected before treatment and after three months, six months, nine months and one year of growth, development, liver function, hepatitis B virologic markers in the detection data. Randomly selected 30 cases of children with chronic hepatitis B patients receiving antiretroviral treatment for children in control group, the largest of the 14-year-old, 4-year-old minimum I licorice diammonium routine therapy, follow-up needed to collect inspection data the same as the treatment group. Randomly selected 31 cases of chronic hepatitis B adult patients receiving antiretroviral treatment for adult control group, the largest of the 56-year-old, the youngest 17-year-old, given lamivudine daily 100mg, regular follow-up, collect the data with the same treatment group . Three groups of patients before treatment were not detected YMDD strain of the virus, HBeAg-positive chronic hepatitis B prevention and treatment of chronic hepatitis B Guide diagnosis developed in accordance with the 2005. 4, the data analysis: the parameters respectively when compared with the t test, χ2 test. Results: 1 year after treatment, the children's treatment group, found no serious adverse reactions, the treatment group and the control group children for children Wechsler Intelligence Scale score, white blood cells, renal Cr height increased weight gain t values ??were: -0.978, -0.74,1.24,0.788,0.703, P values ??were greater than 0.05, the results show that the two groups was statistically no difference in children's growth, development is not affected. 2, the treatment group and adult control group aminotransferase normalization rate of HBVDNA seroconversion rate, HBeAg / HBeAb seroconversion rate YMDD mutation rate χ2 were: 0.11,0.11,0.799,1.45 P values ??greater than 0.05, the results are show two groups statistically no difference between the two groups on the same therapeutic effect. The treatment group and the control group for children 1 year of treatment aminotransferase normalization rates HBeAg / anti HBeAb seroconversion χ2 were: 6.63,5.16, P values ??were less than 0.05 was statistically the two groups are different; treatment group HBVDNA negative was 77.42 percent of children in control group was 0%; show that the effect of treatment in both groups there are obvious differences. YMDD mutation rate of the treatment group 6.45%, 0% in the control group of the Child, the two groups differ. 4 two cases of children with the HBsAg seroconversion one case of HBsAb treatment group and control group patients had this happen. Conclusion: 1, children with chronic hepatitis B lamivudine antiviral therapy safe and effective in the treatment group found no serious adverse reactions, the children's growth, development is not affected. 2, children with chronic hepatitis B using lamivudine treatment effect similar to adults aminotransferase normalization rate after one year of treatment, seroconversion rates, HBVDNA negative rate of YMDD mutation rate statistically, there were no differences. 3, children in the treatment group and the control group: aminotransferase normalization rate, seroconversion rate of HBVDNA negative rate of YMDD mutation rate statistically different. 4, children with chronic hepatitis B with lamivudine antiviral therapy appears HBsAg loss or seroconversion incidence may be more common after treatment than adults to be studied further.
|